• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Companies that Ward Off ESG and Reputation Crises See Value Surge

    3/8/22 8:00:00 AM ET
    $APO
    $CVS
    $FB
    $JNJ
    Investment Managers
    Finance
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $APO alert in real time by email

    PITTSBURGH, March 8, 2022 /PRNewswire-PRWeb/ -- Companies with ESG and reputational risk protection strategies have seen their stock prices rise 5% above the market within two weeks of a reputational challenge, and that premium is almost double for companies that have publicly shared and validated those strategies.

    The study, by Steel City Re, an ESG and reputation insurer, also found that stock prices of firms that managed, validated and publicized ESG and reputation risk management strategies on average gained 9.3% over the subsequent seven months after a precipitating event, while firms in which such processes were in assumed by shareholders to be in place gained 4.3%. Companies that failed to institute, validate, and communicate risk management strategies lost 13.2% of their stock value over those seven-month periods, and they underperformed their peers by an average of 23.3%.

    "Investors appear to reward firms that actively manage reputational risks as operational strategies and not just potential PR problems," said Nir Kossovsky, Steel City Re's CEO. "Our study makes the case for ESG-focused firms to take a more structured, substantive and comprehensive approach to risk governance and management."

    "The data show that instituting, validating, and communicating risk management strategies can both fulfill the goals of stakeholder-centrism and meet shareholder expectations," he added.

    Illustrative highlights include:

    • Johnson & Johnson (NYSE:JNJ) outperformed the market by 16% ($1.7bn) when its much publicized strategic supply chain security and product safety processes were proven effective in 1986.
    • Rolls Royce (OTC:RYCEY), whose board defined its risk governance mission as protecting the reputation, viability, and profitability of the firm, outperformed the market by 14.9% ($3.4bn) after it proved the quality of its safety controls throughout its supply chain in 2011.
    • Apollo Global Management (NYSE:APO) outperformed the market by 16.6% ($1.9bn) after it announced an ESG-focused governance reorganization and presented in 2021 and independent validation of a 3-year investment in reputation risk management.
    • CVS (NYSE:CVS) outperformed the market by 9.3% ($8.6bn) when, presciently anticipating the ESG movement, it pursued an ethical innovative strategy that shunned tobacco products in 2014. It outperformed rivals Walgreens (NYSE:WBA) and Rite Aid (NYSE:RAD) by 16.6% and 24.8% respectively.
    • Apple (NADQ:AAPL) outperformed the market by 24% ($505bn) after introducing innovative ethical privacy features that addressed a critical ESG concern in the technology sector in 2021. It outperformed Meta (NYSE:FB), facing a range of privacy challenges, by 34.9%.

    About the Study

    The Steel Re study looked at seven firms that took direct action to publicize their reputation risk management and governance, 20 firms whose protection strategies were in assumed by shareholders to be in place because of their response to external events, 20 firms whose strategies were shown to be insufficient over seven months, and from among these, 22 firms whose reputational impairment and value losses were measured against peer competitors.

    The reputational challenges were all public events over the past 15 years supplemented by iconic cases of Johnson & Johnson's two Tylenol-related safety events of the 1980's. Individual gains and losses were calculated after normalizing for changes in the S&P500, and the date for ESG and reputational events was determined by a marked surge in stakeholder interest as explored in a related Steel City Re white paper.

    About Steel City Re

    Steel City Re provides parametric ESG insurance, reputational insurance and helps guide companies' boards and senior leadership in developing enhanced risk governance and management practices. Its underwriting model is supported by more than 7.3 million measures of reputational value and traditional financial metrics that also fuel ESG-focused hedge fund strategies. Its risk governance and management models are informed by principles of behavioral economics.

    Media Contact

    Desiree Niccoli, Steel City Re, 412-804-8649, desiree@alschulerpr.com

    Steve Alschuler, Steel City Re, 917-647-2151, steve@alschulerpr.com

     

    SOURCE Steel City Re

    Get the next $APO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APO
    $CVS
    $FB
    $JNJ

    CompanyDatePrice TargetRatingAnalyst
    Johnson & Johnson
    $JNJ
    4/8/2026$250.00Buy
    TD Cowen
    CVS Health Corporation
    $CVS
    3/12/2026$94.00Mkt Perform → Outperform
    Bernstein
    Apollo Global Management Inc. (New)
    $APO
    2/24/2026$142.00Sector Perform
    RBC Capital Mkts
    Johnson & Johnson
    $JNJ
    1/28/2026$262.00Equal-Weight → Overweight
    Morgan Stanley
    Apollo Global Management Inc. (New)
    $APO
    12/11/2025$186.00Buy
    UBS
    Apollo Global Management Inc. (New)
    $APO
    11/20/2025$180.00Equal-Weight → Overweight
    Morgan Stanley
    Johnson & Johnson
    $JNJ
    11/13/2025$230.00Sector Outperform
    Scotiabank
    Johnson & Johnson
    $JNJ
    10/20/2025$203.00Neutral → Outperform
    Daiwa Securities
    More analyst ratings

    $APO
    $CVS
    $FB
    $JNJ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and President, Aetna Nelson Steven H bought $1,289 worth of shares (24 units at $53.70) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    1/27/26 5:20:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP and Chief People Officer Capozzi Heidi B bought $4,589 worth of shares (80 units at $57.36) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    10/14/25 7:08:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Sansone Guy P bought $100,009 worth of shares (1,570 units at $63.70), increasing direct ownership by 15% to 12,007 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    6/9/25 8:22:46 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $APO
    $CVS
    $FB
    $JNJ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Shah Prem S

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    4/2/26 4:58:11 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 4 filed by Newman Brian

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    4/2/26 4:57:02 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 4 filed by Nelson Steven H

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    4/2/26 4:56:13 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $APO
    $CVS
    $FB
    $JNJ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen resumed coverage on Johnson & Johnson with a new price target

    TD Cowen resumed coverage of Johnson & Johnson with a rating of Buy and set a new price target of $250.00

    4/8/26 8:36:42 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CVS Health upgraded by Bernstein with a new price target

    Bernstein upgraded CVS Health from Mkt Perform to Outperform and set a new price target of $94.00

    3/12/26 8:38:26 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    RBC Capital Mkts initiated coverage on Apollo Global Management with a new price target

    RBC Capital Mkts initiated coverage of Apollo Global Management with a rating of Sector Perform and set a new price target of $142.00

    2/24/26 7:45:38 AM ET
    $APO
    Investment Managers
    Finance

    $APO
    $CVS
    $FB
    $JNJ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 12, 2023 - FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products

    For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal

    9/12/23 10:44:21 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

    For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

    5/5/22 4:51:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APO
    $CVS
    $FB
    $JNJ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value

    AUSTIN, Texas, April 09, 2026 (GLOBE NEWSWIRE) -- AINewsWire Editorial Coverage: Pharmaceutical manufacturing is entering a period of structural transformation as regulators impose increasingly stringent expectations around contamination control, data integrity and operational traceability. The European Union's updated GMP Annex 1 guidance places strong emphasis on minimizing human involvement and implementing comprehensive contamination control strategies, requiring manufacturers to evaluate and mitigate risks across personnel, processes and environments. It also encourages the use of barrier systems and automation technologies, reflecting the widely accepted understanding that human oper

    4/9/26 8:30:00 AM ET
    $AMZN
    $JNJ
    $NVDA
    Catalog/Specialty Distribution
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aetna Provider Survey Reveals Optimism and Opportunities to Simplify Health Care

    Optimism exists for the future of health careSurvey highlights opportunities to deepen trust across the provider-payer relationshipFriction points remain, with administrative burden cited as top challengeHARTFORD, Conn., April 8, 2026 /PRNewswire/ -- Aetna®, a CVS Health® company (NYSE:CVS) today announced research findings from the inaugural Aetna Provider Survey, a quarterly study that polls a representative sample of the U.S. provider market to better understand their perceptions, opportunities, and challenges today and into the future. This survey series is intended to solicit timely, objective feedback from the U.S. provider market so we can identify opportunities to change the provider

    4/8/26 6:30:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe

    The VARIPULSE Pro Platform features a new pulse sequence designed to streamline procedures and enhance workflow efficiencyi,ii VARIPULSE Pro to be featured at EHRA 2026 alongside VARIPURE 12-month interim data Johnson & Johnson (NYSE:JNJ) today announced the launch of VARIPULSE Pro in Europe following CE Mark approval, further advancing its pulsed field ablation (PFA) portfolio. This new pulse sequence marks the next evolution of the VARIPULSE Platform and is designed to improve procedural efficiencyi,ii while reinforcing its established safetyiii and effectivenessiv profile. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026

    4/7/26 8:00:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APO
    $CVS
    $FB
    $JNJ
    SEC Filings

    View All

    SEC Form DEF 14A filed by CVS Health Corporation

    DEF 14A - CVS HEALTH Corp (0000064803) (Filer)

    4/3/26 4:05:26 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form DEFA14A filed by CVS Health Corporation

    DEFA14A - CVS HEALTH Corp (0000064803) (Filer)

    4/3/26 4:05:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form SCHEDULE 13G/A filed by Johnson & Johnson

    SCHEDULE 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

    3/26/26 10:05:14 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APO
    $CVS
    $FB
    $JNJ
    Leadership Updates

    Live Leadership Updates

    View All

    Bridge Investment Group Appoints Dugan Fife as Head of Wealth Solutions

    SALT LAKE CITY, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Bridge Investment Group Holdings Inc. ("Bridge" or the "Company"), today announced that Dugan Fife has been appointed Head of Wealth Solutions and Senior Managing Director, effective January 19. Fife will lead the firm's efforts to expand and enhance its wealth solutions platform, delivering innovative investment opportunities and tailored strategies to meet the evolving needs of private wealth clients. Fife joins a high-performing Wealth distribution team at Bridge that serves clients through core investment verticals including Residential, Industrial, Real Estate Credit, and Net Lease. "Dugan's exceptional track record and experience lea

    1/20/26 8:35:00 AM ET
    $APO
    Investment Managers
    Finance

    Stream Data Centers Appoints Michael Lahoud as Chief Executive Officer

    Enhances Leadership Team Across Commercial, Development and Operational Functions to Ramp Up Pace and Scale of Hyperscale Delivery Stream Data Centers ("Stream" or the "Company"), a time-tested hyperscale partner and one of the longest-standing developers in the industry, today announced the appointment of Michael Lahoud as Chief Executive Officer, as the Company continues to scale its platform and expand its capabilities to meet growing customer demand. Lahoud previously served as Co-Managing Partner of Stream and has been with the firm for 15 years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114446486/en/Stream Data C

    1/14/26 9:03:00 AM ET
    $APO
    Investment Managers
    Finance

    CVS Health Helps Improve Access to More Affordable Fertility Treatments

    WOONSOCKET, R.I., Oct. 16, 2025 /PRNewswire/ -- CVS Health (NYSE:CVS) today announced it will support simpler access to more affordable fertility treatments for all Americans through its CVS Specialty Pharmacy and make it easier to pick up fertility medication at its 9,000 community pharmacy locations. CVS Specialty Pharmacy will be a core partner in the TrumpRx Fertility program. As the Trump Administration continues to establish more competitive prices for important medicines, the Administration has engaged with EMD Serono, manufacturer of Gonal-F an in-vitro fertilization (

    10/16/25 5:09:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $APO
    $CVS
    $FB
    $JNJ
    Financials

    Live finance-specific insights

    View All

    CVS Health to hold first quarter 2026 earnings conference call

    WOONSOCKET, R.I., April 6, 2026 /PRNewswire/ -- CVS Health® (NYSE:CVS) will hold a conference call with analysts and investors on Wednesday, May 6th, 2026, at 8:00 a.m. ET to discuss first quarter 2026 financial results. An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where it will be archived for a period of one year.About CVS HealthCVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of December 31, 2025, the

    4/6/26 9:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Realty Income and Apollo to Establish Strategic Partnership

    - Funding Arrangement Will Advance Realty Income's Private Capital Initiative with Leading Asset Manager- Initial Apollo Investment of $1.0 Billion for 49% Equity Interest in Portfolio of Existing U.S. Realty Income Retail Assets- Cost-Efficient Long-Term Equity with 100% Permanent Equity Treatment by Rating AgenciesSAN DIEGO and NEW YORK, March 19, 2026 /PRNewswire/ -- Realty Income Corporation ((Realty Income, NYSE:O), The Monthly Dividend Company®, and Apollo (NYSE:APO) today announced that Apollo-managed funds and affiliates intend to provide a $1.0 billion investment to Realty Income to acquire a 49% interest in a new joint venture entity that is expected to own a diversified portfolio

    3/19/26 4:15:00 PM ET
    $APO
    $O
    Investment Managers
    Finance
    Real Estate Investment Trusts
    Real Estate

    CVS Health declares quarterly dividend

    WOONSOCKET, R.I., March 18, 2026 /PRNewswire/ -- CVS Health® (NYSE: CVS) has announced that its board of directors has approved a quarterly dividend of sixty-six and one-half cents ($0.665 cents) per share on the Common Stock of the Corporation. The dividend is payable on May 4, 2026, to holders of record on April 23, 2026. About CVS HealthCVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of December 31, 2025, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary c

    3/18/26 5:15:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $APO
    $CVS
    $FB
    $JNJ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CVS Health Corporation

    SC 13G - CVS HEALTH Corp (0000064803) (Subject)

    11/13/24 1:00:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc.

    SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

    10/18/24 12:45:41 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form SC 13D/A filed by Walgreens Boots Alliance Inc.

    SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)

    8/20/24 4:05:58 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples